AAADV Workshop

Leaders in clinical and translational cancer research from academia, industry, government and the nonprofit advocacy sectors convene each spring in Bethesda, Maryland, for a unique forum designed to speed cancer treatments to patients. Our three-day, on-site interactive AAADV Workshop offers a mix of small group lectures, moderated discussions, plenary lectures and facilitated case studies of successful drug applications. Participants gain valuable insights on negotiating the spectrum of successful drug development and hone their strategic planning skills with a focus on target validation and pathway identification. The AAADV is the only workshop held in collaboration with the U.S. Food and Drug Administration designed specifically to help, participants understand and negotiate the drug development approval process so that effective cancer treatments can reach patients more quickly.

Who Should Attend

The AAADV Workshop is designed for scientists and consumer advocates with clinical trial experience interested in developing agents for the diagnosis, treatment or prevention of cancer. Individuals with limited experience in the regulatory aspects of oncology drug development will benefit from the knowledge and networking with more-experienced investigators and advocates.

Participants Will:
  • Examine the most urgent issues and meaningful trends in anticancer agent development and
    validation.
  • Learn new approaches for diagnosing, treating and preventing cancer.
  • Benefit from a mix of small group lectures, moderated discussions, facilitated case studies of
    successful new drug applications and plenary lectures.
  • Network with researchers, regulators, patient advocates and others working on the frontlines of
    cancer research and treatment.


A limited number of scholarships will be offered to academic attendees and patient advocates. Applications consist of submission of CV or biosketch, a letter of support from department head or division chief (academics), letter of support from sponsoring organization (advocates), and a statement of intent. To apply for a scholarship see Registration Page.

Fee waivers will be available to government employees. See Registration Page for instructions.

Industry – $2,900

Academic – $2,900*

Patient Advocates $2,900*

Government – $0

*A limited number of scholarships will be offered to academic and patient advocate applicants. See Scholarships page for more information.

Applicants will be notified of approval within 5 [five] working days of submission of application. See Scholarships page for more information.

Cancellation Policy:

Full refund if cancelled by March 31, 2017. $1,450 refund if cancelled by April 21, 2017. No refund after this date.

 

 

 

Executive Committee

Scholars pages_Rev
H. Kim Lyerly, M.D.AAADV Chair, Duke University
Scholars pages_Rev
Richard Pazdur, M.D.U.S. Food and Drug Administration
Gregory Reaman, M.D.U.S. Food and Drug Administration
Scholars pages_Rev
Mary Scroggins, M.A. Pinkie Hugs, LLC; In My Sister’s Care
Scholars pages_Rev
Julia Beaver, M.D.U.S. Food and Drug Administration
Scholars pages_Rev
Julie Bullock, Pharm.D.d3 Medicine, a Certara Company
Scholars pages_Rev
Renzo Canetta, M.D.Independent Consultant
Scholars pages_Rev
Helen Chen, M.D.National Cancer Institute
Scholars pages_Rev
Meredith Chuk, M.D.U.S. Food and Drug Administration
Scholars pages_Rev
Lola Fashoyin-Aje, M.D., M.P.H.U.S. Food and Drug Administration
Scholars pages_Rev
Howard Fingert, M.D.Takeda Oncology
Scholars pages_Rev
Thomas Fleming, Ph.D.University of Washington
Scholars pages_Rev
Joseph Gootenberg, M.D.U.S. Food and Drug Administration
Scholars pages_Rev
Axel Hoos, M.D., Ph.D.GlaxoSmithKline
Scholars pages_Rev
Pasi A. Jänne, M.D., Ph.D.Harvard Medical School
Scholars pages_Rev
Sean Khozin, M.D., M.P.H.U.S. Food and Drug Administration
Scholars pages_Rev
Virginia Kwitkowski, M.S., ANCP-BCU.S. Food and Drug Administration
Scholars pages_Rev
Ke Liu, M.D., Ph.D.U.S. Food and Drug Administration
Scholars pages_Rev
Patricia LoRusso, D.O.Yale University
Scholars pages_Rev
Tatiana Prowell, M.D.U.S. Food and Drug Administration
Scholars pages_Rev
Richard Schilsky, M.D.American Society of Clinical Oncology
Scholars pages_Rev
Sarah Schrieber, Pharm.D.U.S. Food and Drug Administration
Scholars pages_Rev
Rajeshwari Sridhara, Ph.D.U.S. Food and Drug Administration
Scholars pages_Rev
Joohee Sul, M.D.U.S. Food and Drug Administration
Scholars pages_Rev
Jura Viesulas, Ed.D.U.S. Food and Drug Administration
Scholars pages_Rev
Jeffrey Weber, M.D., Ph.D.New York University

Accreditation Statement

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement

AACR has designated this live activity for a maximum of 21.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming (CME) Credit

Physicians and other health care professionals seeking AMA PRA Category 1 Credits™ for this continuing medical education activity must complete the online CME Request for Credit Survey by Friday, June 16, 2017
Certificates will only be issued to those who complete the survey. The Request for Credit Survey is available at the link below and via email.
Your CME certificate will be sent to you via email after the completion of the activity.

Statement of Educational Need, Target Audience, and Learning Objectives:

This course provides a comprehensive review of agent (including drugs and biological) development including pre-clinical and clinical evaluation, and regulatory procedures and endpoints required to bring discovery into clinical use that provide benefit to patients. Few individual investigators have this entire scope of this knowledge, and this workshop integrates this knowledge with real-life examples, and specifically illustrates the role that the community, including the investigator plays in the process from discovery and approvals and beyond. Only one agent is successfully produced for every 20 that enter into clinical evaluation. The workshop will impart the knowledge necessary to enable successful clinical researchers to develop the expertise in the entire spectrum of drug development by honing strategic planning skills with a focus on target validation and pathway identification that will lead to advances in the entire field of cancer research.

This workshop:

  • seeks to improve the efficiency of testing and increase the success rate of development plans for agents that provide benefit to patients,
  • provides an opportunity for open dialogue between regulatory agencies, the oncology community including physician-scientists,
  • encourages creative thinking in addressing current challenges and developing useful and informative oncology clinical trials.

Following this learning activity, participants should be able to:

  • Assess the key decision points in determining if an anticancer agent or combination has clinical benefit.
  • Analyze and more effectively follow FDA safety and efficacy guidelines during the development and clinical testing of anticancer and cancer prevention drugs, and in the long term safety evaluation of these.
  • Design, and participate in oncology clinical trials with meaningful endpoints and accrual goals.
Disclosure Statement

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this workshop.

Questions about CME?

Please contact the AACR Office of CME at (215) 440-9300 or cme@aacr.org.


Sponsors